ArticleJHEP reports : innovation in hepatology2026

Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study.

Ciro Celsa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.